camostat has been researched along with Vascular Diseases in 1 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teraoka, S | 1 |
| Takahashi, K | 1 |
| Toma, H | 1 |
| Yagisawa, T | 1 |
| Yamaguchi, Y | 1 |
| Sanaka, T | 1 |
| Fuchinoue, S | 1 |
| Honda, H | 1 |
| Kawai, T | 1 |
| Tanabe, K | 1 |
1 other study available for camostat and Vascular Diseases
| Article | Year |
|---|---|
New approach to management of chronic vascular rejection with prostacyclin analogue after kidney transplantation.
Topics: alpha-Cyclodextrins; Benzamidines; Blood Platelets; Cyclodextrins; Epoprostenol; Esters; Gabexate; G | 1987 |